QCG
LXRX icon

Quadrant Capital Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Quadrant Capital Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,371
Closed -$2.15K – 2771
2024
Q3 		$2.15K Hold
1,371
– – ﹤0.01% 2488
2024
Q2 		$2.3K Hold
1,371
– – ﹤0.01% 2450
2024
Q1 		$3.29K Hold
1,371
– – ﹤0.01% 2407
2023
Q4 		$2.1K Buy
+1,371
New +$1.63K ﹤0.01% 2465

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Quadrant Capital Group's LXRX Position: Q4 2024 in Review

Quadrant Capital Group sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2024, closing a stake of 1,371 shares — an estimated $2.15K sold.

Quadrant Capital Group first reported a position in LXRX in Q4 2023 and held it in 4 quarters. The position peaked at $3.29K in Q1 2024. 127 funds tracked by Wall St. Rank hold LXRX as of Q4 2024.

  • Quadrant Capital Group reported no remaining Lexicon Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 1,371 Lexicon Pharmaceuticals shares in Q4 2024, an estimated $2.15K.
  • Quadrant Capital Group first reported a position in Lexicon Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Quadrant Capital Group's Lexicon Pharmaceuticals position peaked at $3.29K in Q1 2024.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2024.

Based on Quadrant Capital Group's 13F filing for Q4 2024, filed 13 Feb 2025.